Treatment of anemia in low-risk myelodysplastic syndromes with amifostine. In vitro testing of response

Annals of Hematology

Volumn 81, Issue 4, 2002, Pages 182-186

  Viniou, N ^a   Terpos, E ^b   Galanopoulos, A ^c   Kritikou Griva, E ^c   Akel, S ^a   Michalis, E ^c   Apostolidou, E ^a   Georgiadou, D ^d   Kouraklis, A ^e   Parharidou, A ^f   Kokkini, G ^d   Symeonidis, A ^e   Anagnostopoulos, N I ^c   Christakis, J I ^g   Tasiopoulou, A ^c   Loukopoulos, D ^a   Yataganas, X ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b 251 GENERAL AIR FORCE HOSPITAL   (Greece)

^c G GENNIMATAS GENERAL HOSPITAL   (Greece)

^d SISMANOGLIO HOSPITAL   (Greece)

^e UNIVERSITY OF PATRAS   (Greece)

^f AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

^g THEAGENIO CANCER HOSPITAL   (Greece)

Author keywords

Amifostine; Myelodysplastic syndrome; Refractory anemia; Refractory anemia with excess of blasts; Sideroblastic anemia

Indexed keywords

AMIFOSTINE; AZACITIDINE; CIPROFLOXACIN; CYTARABINE; DEXAMETHASONE; HEMOGLOBIN; PENTOXIFYLLINE; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; BONE MARROW CELL; BURST FORMING UNIT E; CLINICAL ARTICLE; CLONOGENIC ASSAY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; FATIGUE; FEMALE; HEMATOPOIESIS; HEMOGLOBIN DETERMINATION; HIGH RISK PATIENT; HUMAN; HYPOTENSION; IN VITRO STUDY; MALE; MYELODYSPLASTIC SYNDROME; NAUSEA; PREDICTION; PRIORITY JOURNAL; REFRACTORY ANEMIA; SIDEROBLASTIC ANEMIA; VOMITING;

AGED; AGED, 80 AND OVER; AMIFOSTINE; ANEMIA, REFRACTORY; BONE MARROW CELLS; COLONY-FORMING UNITS ASSAY; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROID PROGENITOR CELLS; FEMALE; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS;

EID: 0036935346     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-002-0442-y     Document Type: Article

References (22)

1. Bowen DT, Denzlinger C, Brugger W, Culligan D, Gelly K, Adlakha S, Groves M, Hepburn M, Kanz L (1998) Poor response rate to a continuous schedule of Amifostine therapy for "low/intermediate risk" myelodysplastic patients. Br J Haematol 103:785-787
2. Cazzola M, Anderson J, Ganser A, Hellstrom-Lindberg E (1998) A patient oriented approach to treatment of myelodysplastic syndromes. Haematologica 83:910-935
3. Dansey R (2000) Myelodysplasia. Curr Opin Oncol 12:13-21
4. Fontenay-Roupie M, Bouscary D, Guesnu M, Picard F, Melle J, Lacombe C, Gisselbrecht S, Mayeux P, Dreyfus F (1999) Ineffective erythropoiesis in myelodysplastic syndromes: correlation with Fas expression but not with lack or erythropoietin receptor signal transduction. Br J Haematol 106:464-473
5. Galanopoulos A, Kritikou-Griva E, Gligori J, Michalis E, Grigoraki V, Marinakis T, Kakkas J, Tasiopoulou A, Anagnostopoulos NI (2001) Treatment of patients with myelodysplastic syndrome with amifostine. Leuk Res 25:665-671
6. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079-2088
7. Greenberg P (2001) Implications of pathogenetic and prognostic features for management of myelodysplastic syndromes. Lancet 357:1059-1060
8. Grossi A, Fabbri A, Santini V, Leoni F, Nozzoli C, Longo G, Pagliai G, Ciolli S, Ferrini PR (2000) Amifostine in the treatment of low-risk myelodysplastic syndromes. Haematologica 85:367-371
9. Hellstrom-Lindberg E (2000) Treatment of adult myelodysplastic syndromes. Int J Hematol 70:141-154
10. Hofmann WK, Seipelt G, Ottmann OG, Kalina U, Koschmieder S, Brucher J, Frickhofen N, Klausman M, Mitrou PS, Hoelzer D (2000) Effect of treatment with amifostine used as a single agent in patients with refractory anemia on clinical outcome and serum tumor necrosis factor α levels. Ann Hematol 79:255-258
11. Korst AE, Eeltink CM, Vermorken JB, van der Vijgh WJ (1997) Pharmacokinetics of amifostine and its metabolites in patients. Eur J Cancer 33:1425-1429
12. List AF, Brasfield F, Heaton R, Glinsmann-Gibson B, Crook L, Taetle R, Capizzi R (1997) Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndromes. Blood 90:3364-3369
13. List AF (1998) Hematopoietic stimulation by amifostine and sodium phenylbutyrate: what is the potential in MDS? Leuk Res 22: S7-S11
14. List AF, Heaton R, Gibson BG, Capizzi R (1998) Amifostine stimulates formation of multipotent and erythroid bone marrow progenitors. Leukemia 12:1596-1602
15. List AF, Holmes H, Greenberg PL, Bennett JM, Oster W (1999) Phase II study of amifostine in patients with myelodysplastic syndromes (MDS). Blood 94 (Suppl 1):305a (abstract)
16. Orkin SH, Harosi FI, Leder P (1975) Differentiation in erythroleukemic cells and their somatic hybrids. Proc Natl Acad Sci USA 72:98-102
17. Parker JE, Mufti GJ (1998) Ineffective haemopoiesis and apoptosis in myelodysplastic syndromes. Br J Haematol 101: 220-230
18. Raza A, Qawi H, Lisak L, Andric T, Dar S, Andrews C, Venugopal P, Gezer S, Gregory S, Loew J, Robin E, Rifkin S, Hsu WT, Huang RW (2000) Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone. Blood 95:1580-1587
19. Ribizzi I, Darnowski JW, Goulette FA, Sertoli MR, Calabresi P (2000) Amifostine cytotoxicity and induction of apoptosis in a human myelodysplastic cell line. Leuk Res 24:519-525
20. Romano MF, Lamberti A, Bisogni R, Garbi C, Pagnano AM, Auletta P, Tassone P, Turco MC, Venuta S (1999) Amifostine inhibits hematopoietic progenitor cell apoptosis by activating NF-κB/Rel transcription factors. Blood 94:4060-4066
21. Tefferi A, Elliott MA, Steensma DP, Hook CC, Dispenzieria A, Hanson CA, Schroeder G, Letendre L (2001) Amifostine alone and in combination with erythropoietin for the treatment of favorable myelodysplastic syndrome. Leuk Res 25:183-185
22. Tsiara SN, Kapsali HD, Panteli K, Christou L, Bourantas KL (2001) Preliminary results of amifostine administration in combination with recombinant human erythropoietin in patients with myelodysplastic syndromes. J Exp Clin Cancer Res 20:35-38